Compass Wealth Management LLC Reduces Holdings in Medtronic PLC $MDT

Compass Wealth Management LLC trimmed its stake in shares of Medtronic PLC (NYSE:MDT) by 96.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,379 shares of the medical technology company’s stock after selling 42,772 shares during the quarter. Compass Wealth Management LLC’s holdings in Medtronic were worth $131,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of MDT. Delos Wealth Advisors LLC bought a new position in shares of Medtronic in the second quarter worth approximately $27,000. Corundum Trust Company INC purchased a new stake in Medtronic during the 3rd quarter valued at $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medtronic in the third quarter valued at about $33,000. Tripletail Wealth Management LLC bought a new position in shares of Medtronic during the third quarter valued at about $34,000. Finally, GFG Capital LLC bought a new position in shares of Medtronic during the second quarter valued at about $36,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $100.71 on Wednesday. The company’s fifty day moving average price is $99.52 and its 200-day moving average price is $95.48. The stock has a market cap of $129.12 billion, a PE ratio of 27.15, a price-to-earnings-growth ratio of 2.65 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the business earned $1.26 EPS. Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MDT shares. Citigroup raised their target price on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. UBS Group upped their target price on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Finally, TD Cowen restated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Fourteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.28.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).